Zingo provides fast-acting topical, local analgesia, to reduce the pain associated with venous access procedures, such as IV insertions or blood draws, in children three to 18 years of age.
Under the agreement, which will last three years, Sagent will join with Anesiva to co-promote Zingo within hospitals as well as facilitating contract negotiations with hospitals and group purchasing organizations. Sagent’s team will focus their selling efforts toward hospital pharmacists, with Anesiva promoting primarily to physicians and nurses.
Sagent will manage Zingo warehousing and distribution services. The terms of the agreement provide for Sagent to earn a royalty based on Anesiva’s net sales of Zingo, and for Anesiva to reimburse Sagent for certain direct expenses. Anesiva may designate additional marketing partners to address non-hospital affiliated markets.
John McLaughlin, CEO of Anesiva, said: “Together with Anesiva’s experienced marketing organization and planned sales force of 15 representatives, we will have complementary roles and provide synergistic selling efforts to launch Zingo successfully in US hospitals. Anesiva will also leverage Sagent’s established infrastructure for warehousing and distribution services.”